FDA Clears Vivos Therapeutics' Breakthrough Sleep Apnea Treatment

Vivos Therapeutics has achieved a significant milestone with its first-ever 510(k) clearance from the FDA for the treatment of severe obstructive sleep apnea (OSA) in adults using its removable CARE oral appliances. This clearance allows Vivos to offer an alternative treatment option to patients with severe OSA, providing an alternative to CPAP therapy or surgical neurostimulation implants. It is the first time the FDA has granted approval for an oral appliance to treat both moderate and severe OSA in adults aged 18 and older. Vivos Therapeutics aims to improve the quality of life for individuals suffering from sleep apnea by providing effective and accessible treatment options.